Mostrar el registro sencillo del ítem
dc.contributor.author | Moens, B. | |
dc.contributor.author | Decanine, D. | |
dc.contributor.author | Menezes, S.M. | |
dc.contributor.author | Khouri, R. | |
dc.contributor.author | Silva-Santos, G. | |
dc.contributor.author | Lopez, G. | |
dc.contributor.author | Alvarez, C. | |
dc.contributor.author | Talledo Albujar, Michael John | |
dc.contributor.author | Gotuzzo Herencia, José Eduardo | |
dc.contributor.author | de Almeida Kruschewsky, R. | |
dc.contributor.author | Galvão-Castro, B. | |
dc.contributor.author | Vandamme, A.-M. | |
dc.contributor.author | van Weyenbergh, J. | |
dc.date.accessioned | 2022-01-18T19:34:38Z | |
dc.date.available | 2022-01-18T19:34:38Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/11078 | |
dc.description.abstract | Background: Clear therapeutic guidelines for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) are missing due to the lack of randomized double-blind controlled clinical trials. Moderate yet similar clinical benefit has been demonstrated for IFN-α and high-dose ascorbic acid (AA) monotherapy in a large open clinical trial. However, there is a lack of in vivo and in vitro studies exploring and comparing the effects of high-dose AA and IFN-α treatment in the context of HAM/TSP. Therefore, we performed the first comparative analysis of the ex vivo and in vitro molecular and cellular mechanisms of action of IFN-α and high-dose AA in HAM/TSP. Principal Findings: Through thymidine incorporation and quantification of Th1/Th2/Th17 cytokines, we demonstrate that high-dose AA displays differential and superior antiproliferative and immunomodulatory effects over IFN-α in HAM/TSP PBMCs ex vivo. In addition, high-dose AA, but not IFN-α, induced cell death in both HAM/TSP PBMCs and HTLV-1-infected T-cell lines MT-2 and MT-4. Microarray data combined with pathway analysis of MT-2 cells revealed AA-induced regulation of genes associated with cell death, including miR-155. Since miR-155 has recently been demonstrated to up-regulate IFN-γ, this microRNA might represent a novel therapeutic target in HAM/TSP, as recently demonstrated in multiple sclerosis, another neuroinflammatory disease. On the other hand, IFN-α selectively up-regulated antiviral and immune-related genes. Conclusions: In comparison to IFN-α, high-dose AA treatment has superior ex vivo and in vitro cell death-inducing, antiproliferative and immunomodulatory anti-HTLV-1 effects. Differential pathway activation by both drugs opens up avenues for targeted treatment in specific patient subsets. | en_US |
dc.language.iso | eng | |
dc.publisher | Public Library of Science | |
dc.relation.ispartofseries | PLoS Neglected Tropical Diseases | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Humans | en_US |
dc.subject | comparative study | en_US |
dc.subject | controlled study | en_US |
dc.subject | in vitro study | en_US |
dc.subject | nucleotide sequence | en_US |
dc.subject | flow cytometry | en_US |
dc.subject | gamma interferon | en_US |
dc.subject | HTLV 1 associated myelopathy | en_US |
dc.subject | peripheral blood mononuclear cell | en_US |
dc.subject | Th1 cell | en_US |
dc.subject | Th2 cell | en_US |
dc.subject | tropical spastic paraparesis | en_US |
dc.subject | human cell | en_US |
dc.subject | signal transduction | en_US |
dc.subject | upregulation | en_US |
dc.subject | drug effect | en_US |
dc.subject | interleukin 10 | en_US |
dc.subject | interleukin 2 | en_US |
dc.subject | interleukin 4 | en_US |
dc.subject | interleukin 6 | en_US |
dc.subject | tumor necrosis factor alpha | en_US |
dc.subject | Cells, Cultured | en_US |
dc.subject | leukocyte count | en_US |
dc.subject | immunomodulation | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | alpha interferon | en_US |
dc.subject | T cell leukemia | en_US |
dc.subject | antiproliferative activity | en_US |
dc.subject | Gene Expression Profiling | en_US |
dc.subject | cell death | en_US |
dc.subject | interleukin 17 | en_US |
dc.subject | Antineoplastic Agents | en_US |
dc.subject | Spinal Cord Diseases | en_US |
dc.subject | lymphocyte proliferation | en_US |
dc.subject | alpha2a interferon | en_US |
dc.subject | Ascorbic Acid | en_US |
dc.subject | Cell Death | en_US |
dc.subject | DNA synthesis | en_US |
dc.subject | gene control | en_US |
dc.subject | Immunologic Factors | en_US |
dc.subject | Interferon-alpha | en_US |
dc.subject | Leukemia-Lymphoma, Adult T-Cell | en_US |
dc.subject | Microarray Analysis | en_US |
dc.subject | microRNA 155 | en_US |
dc.subject | Organ Culture Techniques | en_US |
dc.subject | Th17 cell | en_US |
dc.title | Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1371/journal.pntd.0001729 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.06 | |
dc.relation.issn | 1935-2735 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |